Bio View Statistics
Bio View (BIOV) Stock Statistics & Valuation Metrics
Total Valuation
Bio View has a market cap or net worth of ILA 7.54M. The enterprise value is ILA 11.95T.
- Market Cap
- ILA 7.54M
- Enterprise Value
- ILA 11.95T
Share Statistics
Bio View has 155,367 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 155,367
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Bio View’s return on equity (ROE) is -1.63 and return on invested capital (ROIC) is -62.01%.
- Return on Equity (ROE)
- -1.63
- Return on Assets (ROA)
- -0.77
- Return on Invested Capital (ROIC)
- -62.01%
- Return on Capital Employed (ROCE)
- -0.69
- Revenue Per Employee
- 664.33K
- Profits Per Employee
- -511.07K
- Employee Count
- 30
- Asset Turnover
- 1.00
- Inventory Turnover
- 1.84
Valuation Ratios
The current PE Ratio of Bio View is -0.51. Bio View’s PEG ratio is 0.02.
- PE Ratio
- -0.51
- PS Ratio
- 0.36
- PB Ratio
- 0.99
- Price to FCF
- 15.29
- Price to Operating Cash Flow
- 12.88
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Bio View had revenue of 19.93M and earned -15.33M in profits. Earnings per share was -110.00.
- Revenue
- 19.93M
- Gross Profit
- 8.75M
- Operating Income
- -7.80M
- Pretax Income
- -9.15M
- Net Income
- -15.33M
- EBITDA
- -7.19M
- Earnings Per Share (EPS)
- -110.00
Cash Flow
In the last 12 months, operating cash flow was 518.00K and capital expenditures -25,000, giving a free cash flow of 493.00K billion.
- Operating Cash Flow
- 518.00K
- Free Cash Flow
- 493.00K
- Free Cash Flow per Share
- 3.58
Dividends & Yields
Bio View pays an annual dividend of ILA 200.00, resulting in a dividend yield of ―
- Dividend Per Share
- ILA 200.00
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.54%
- Earnings Yield
- -196.39%
Stock Price Statistics
- Beta
- 0.22
- 52-Week Price Change
- -64.85%
- 50-Day Moving Average
- 6655.42
- 200-Day Moving Average
- 11732.75
- Relative Strength Index (RSI)
- 38.27
- Average Volume (3m)
- 3,183
Important Dates
Bio View upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- ―
- Next Earnings Date
- ―
- Ex-Dividend Date
- Mar 22, 2017
Financial Position
Bio View as a current ratio of 1.88, with Debt / Equity ratio of 29.67%
- Current Ratio
- 1.88
- Quick Ratio
- 1.17
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.30
- Interest Coverage Ratio
- -33.63
Taxes
In the past 12 months, Bio View has paid 6.18M in taxes.
- Income Tax
- 6.18M
- Effective Tax Rate
- -0.68
Enterprise Valuation
Bio View EV to EBITDA ratio is -1.29, with an EV/FCF ratio of 8.00.
- EV to Sales
- 0.19
- EV to EBITDA
- -1.29
- EV to Free Cash Flow
- 8.00
- EV to Operating Cash Flow
- 7.61
Balance Sheet
Bio View has ILA 8.17M in cash and marketable securities with ILA 2.10M in debt, giving a net cash position of ILA 6.07M billion.
- Cash & Marketable Securities
- ILA 8.17M
- Total Debt
- ILA 2.10M
- Net Cash
- ILA 6.07M
- Net Cash Per Share
- ILA 39.06
- Tangible Book Value Per Share
- ILA 48.81
Margins
Gross margin is 49.29%, with operating margin of -23.34%, and net profit margin of -63.32%.
- Gross Margin
- 49.29%
- Operating Margin
- -23.34%
- Pretax Margin
- -30.16%
- Net Profit Margin
- -63.32%
- EBITDA Margin
- -14.81%
- EBIT Margin
- -23.16%
Analyst Forecast
The average price target for Bio View is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 15.77%
- EPS Growth Forecast
- -31.40%

